was successfully added to your cart.

Your SEO optimized title page contents

International Cannabinoid Research Symposium 2013 Overview

Quantum 9, medical marijuana consulting and grow automation technology firm, attended the ICRS 2013 conference in Vancouver, British Columbia from June 21 – 26, 2013. The event marked the 23rd Annual International Cannabinoid Research Society Symposium on the cannabinoid sciences. The event was less successful than previous years due to the lack of funding in the cannabinoid sciences field. This was evident in the sample sizes of the laboratory research studies and overall attendance. The event was not cheap, $1,125 per attendee plus $58 an evening stay, for five days, on University of British Columbia Campus. There was an additional charge of $150 for attending the Clinical Day on top of all of the other charges including international fees.

Flight to BC

My personal journey started in Chicago where I sat next to one of the most brilliant up and coming cannabinoid research scientist. On the plane ride, I quickly found out we shared similar passions in the cannabis field. He taught me about science and medical breakthroughs, the medical vernacular, and I taught him about the cannabis plant itself. Our conversations were mind blowing, and we became instant friends. We spoke at length about Quantum 9’s cannabis consulting practice, and I actually helped him with this PowerPoint presentation during our five hour flight to the beautiful city of Vancouver. Pritesh went on to win an award for one of the best oral presentations at the conference. I’m not going to be as bold as saying I had much to do with Pritesh’s win, but I will say that my help didn’t hurt. Unfortunately, during his cutting edge, groundbreaking, award winning presentation I was not in attendance due to back issues. I recently had a lumbar laminectomy to address a L4/L5 and L5/S1 herniated discs. The worst part is that Pritesh gave Quantum 9 a shout out during his presentation, and I wasn’t there to witness it. Pritesh ‘s research focuses on the integration of computer modeling and pharmacological testing of compounds to identify novel leads for the G Protein-Coupled cannabinoid receptors CB1 and CB2, which have been shown to regulate a broad spectrum of physiological conditions from regulating appetite to pain. His study and presentation focused on the Identification of Raloxifene as a Novel CB2 Inverse Agonist. Basically, to sum this up in layman’s terms; Pritesh’s study found that Raloxifene (marketed as Evista by Eli Lilly and Company), an FDA approved drug that is used for the treatment and prevention of osteoporosis in post-menopausal women, is acting on the cannabinoid receptor 2 (CB2). . The dirt: Pritesh identified that an FDA approved is acting on a target other than which it is marketed for which could help explain the known therapeutic effects of this drug for treating / preventing post-menopausal osteoporosis.

 

Upon arriving Ed Rosenthal and I traveled down to the UBS Art Museum where the official reception was held for event goers. We spent a considerable amount of time with the lovely Sita von Windheim. After the reception, we connected with a client to discuss Canadian Marihuana for Medical Purposes Regulations Consulting. The Client needed information pertaining to talent acquisition to good production planning and cultivation best practices. We helped educate him on the first steps in the process. Day two involved a lot of hand shaking and the introduction to Ron Mullins of California NORML, Dr. Dave Allen and Joel from Urban Grower Online. Day three involved an on-site visit to the Urban Grower’s cultivation center. After the grow tour,  we enjoyed a nice meal with the group. Day four Ed and I hit the conference hard and afterwards a group of us headed downtown Vancouver to the local watering holes Steamworks Brewery and Lamplighter Pub. Day five, six and seven we met with another group in Kelowna, Canada where Desert Squirrel and Ed Roshental tag teamed an epic 80 light CCH20 Under Current cultivation facility. It was magical watching two of the most respected cultivators explain complex molecular subjects with such simplicity and elegance. The team consulted subjects from water filtration to light optimization.

We made a tremendous amount of contacts and learned many cutting edge cannabinoid treatment advances in the field; I was blessed to be a part of such an amazing event and speaking with some of the most brilliant minds in the cannabinoid research field.

Quantum 9 is the most trusted name in cannabis consulting. Call us today to setup a time to chat with one of our expert cultivation experts. 

About Michael Mayes

As Chief Executive Officer for Quantum 9, Inc., Michael has assisted in funding some of the largest commercial cannabis projects in the world. Michael has been a cannabis investor since 2009 in Colorado’s first legal for-profit cannabis market. As the co-founder and CEO of Quantum 9, Inc., Michael has spent years designing technology and collaborating with countless consultants on the forefront of the cannabis industry. Collaborating with the brightest minds and contributing to world-class organizations has been an incredibly enlightening and rewarding experience for him. Also, he has amassed a comprehensive and award-winning team engaged globally for public policy best practices through the prioritization of environmental sustainability and patient care. Michael is a member of the International Cannabinoid Research Society (ICRS), contributor to Marijuana Business Daily, quoted in the Chicago Tribune, Tampa Tribune, Yahoo Finance, Tampa Tribune, Sativa Magazine, CBC and the Daily Herald. His media appearances include several CBS and WGN appearances and international presence on BNN Commodities in Canada. On the public policy front, Michael and his team were instrumental in their work of drafting the Kentucky Medical Marijuana Bill for Senator Perry Clark. Most recently, Michael taught a class for the International Pharmaceutical Academy in Toronto, Canada. He spoke on Cannabis Pharmacology, and the effects cannabis has on the endocannabinoid system.

Leave a Reply